StockData
Absci Corp logo

Absci Corp (ABSI) stock

ABSINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$7.58+0.11 (+1.40%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Absci r&d expenses

Research and development expenses are spending on new products and technology.

Absci's R&D Expenses for the twelve months ending Jun 30, 2026 was $86.49M, up 18.2% year over year. For fiscal 2025 it was $81.42M, up 27.5% from the year before. The highest annual figure on record is $81.42M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$81.42M+27.5%
FY2024Dec 31, 2024$63.86M+32.9%
FY2023Dec 31, 2023$48.07M-18.4%
FY2022Dec 31, 2022$58.91M+32.1%
FY2021Dec 31, 2021$44.59M+289.5%
FY2020Dec 31, 2020$11.45M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.62M+10.5%
Q1 FY2026Mar 31, 2026$19.28M+17.8%
Q4 FY2025Dec 31, 2025$25.35M+37.9%
Q3 FY2025Sep 30, 2025$19.25M+7.0%
Q2 FY2025Jun 30, 2025$20.46M+34.1%
Q1 FY2025Mar 31, 2025$16.36M+33.7%
Q4 FY2024Dec 31, 2024$18.38M+49.8%
Q3 FY2024Sep 30, 2024$17.99M+63.1%
Q2 FY2024Jun 30, 2024$15.26M+26.0%
Q1 FY2024Mar 31, 2024$12.24M-3.3%
Q4 FY2023Dec 31, 2023$12.27M+8.4%
Q3 FY2023Sep 30, 2023$11.03M-29.0%
Q2 FY2023Jun 30, 2023$12.11M-25.4%
Q1 FY2023Mar 31, 2023$12.66M-20.0%
Q4 FY2022Dec 31, 2022$11.32M-28.2%
Q3 FY2022Sep 30, 2022$15.53M+44.7%
Q2 FY2022Jun 30, 2022$16.24M+47.1%
Q1 FY2022Mar 31, 2022$15.83M+124.5%
Q4 FY2021Dec 31, 2021$15.77M+243.0%
Q3 FY2021Sep 30, 2021$10.73M+298.6%
Q2 FY2021Jun 30, 2021$11.04M+390.2%
Q1 FY2021Mar 31, 2021$7.05M–
Q4 FY2020Dec 31, 2020$4.60M–
Q3 FY2020Sep 30, 2020$2.69M–
Q2 FY2020Jun 30, 2020$2.25M–

More Absci figures

See a number that looks wrong?